Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardised by Brexit.
A new report yesterday (22 May) showed the United Kingdom was well ahead of rivals like Germany, France and Switzerland in terms of the number of experimental drugs in clinical development at early-stage biotech firms.
Image: Biotech-produced drugs are becoming more and more popular. (Brainco Social Media/Flickr)
